质子泵抑制剂与抗血小板药物联用的安全性

[3] Anderson JL,Adams CD,Antman EM,et al.ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction:a report of the American College of Cardiology/American Heart Association Task Force on Practise Guidelines(Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction)developed in collaboration with the  American College of  Emergency Physicians,the Society for Cardiovascular Angiography and Interventions,and the  Society of Thoracic Surgeons endorsed by the  American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine.J Am Coll Cardiol.2007;50:e1-e157.
[4] Steinhubl SR,Berger PB,Mann JT 3rd,et al.Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention:a randomized controlled trial.JAMA.2002;288:2411-2420.
[5] Lai KC,Chu KM,Hui WM,et al.Esomeprazole with aspirin versus clopidogrel for prevetion of recurrent gastrointestinal ulcer complications.Clin Gastroenterol Hepatol.2006;4:860-865.
[6] Bhatt DL,Scheiman J,Abraham NS,et al.ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use:a report of the  American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents.Circulation.2008;118:1894-1909.
[7] Gilard M,Arnaud B,Le Gal G,Abgrall JF,Boschat J.Influence of omeprazoel on the antiplatelet action of clopidogrel associated with aspirin.J Thromb Haemost.2006;4:2508-2509.
[8] Gilard M,Arnaud B,Cornily JC,et al.Influence of omeprazoel on the antiplatelet action of clopidogrel associated with aspirin:the randomized,double-blind OCLA(Omeprazole Clopidogrel Aspirin)study.J Am Coll Cardiol.2008;51:256-260.
[9]  Ho PM,Maddox TM,Wang L,et al.Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrom.JAMA.2009;301:937-944.
[10] Kreutz RP,Stanek EJ,Aubert R,et al.Impact of  proton pump inhibitors on the effectiveness of clopidogrel after cononary stent placement: the clopidogrel medco outcomes study.Pharmacotherapy.2010;30:787-796.
[11] United States Food and Drug Administration.FDA drug safety Communication: early communication about an ongoing safety review of clopidogrel bisulfate (marked as Plavix).Available online at http://www.fda.gov/Drugs/DrugSafety/PostmarketDurgSafetyInformationforPatientsandProvider/DurgSafetyInformationforHealthcareProfessionals/ucm079520.htm
[12] Desta Z,Zhao X,Shin JG,Flockhart DA.Clinical significance of the cytochrome P450 2C19 genetic polymorphism.Clin Pharmacokenet.2002;41:913-958.
[13] Mega JL,Simon T,Anderson JL,et al.CYP2C19 genetic variants and clinical outcomes with clopidogrel: a collaborative meta-analysis.Circulation.2009;120:S598-S599.
[14] Simon T,Verstuyft C,Mary-Krause M,et al.Genetic determinants of response to clopidogrel and cardiovascular events.N Eng J Med.2009;360：363-375.
[15] Simon T,Steg PG,Gilard M,et al.Clinical events as a function of proton pump inhibitor use,clopidogrel use,and cytochrome P450 2C19 genotype in a large nation-wide cohort of acute myocardial infarction results.Circulation.2011;123:474-482.
[16]O’Donoghue ML,Braunwald E,Antman EM,et al.Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomized trials.Lancet.2009;374:989-997.
[17] Bhatt DL,Cryer BL,Contant CF,et al.Clopidogrel with or without omeprazole in coronary artery disease.N Engl J Med.2010;363:1909-1917.
[18] Hsu PI,Lai KH,Liu CP.Esomeprazole with clopidogrel reduces peptic ulcer recurrance,compared with clopidogrel alone,in patients with atherosclerosis.Gastroenterology.2011;140:791-798.
[19] Abraham NS,Hlatky MA,Antman EM,et al.ACCF/ACG/AHA 2010 expert consesus document on the concomitant use of proton punp inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consesus document on reducing the gastointestinal risks of antiplatelet therapy an NSAID use.Am J Gastroenterol.2010;105:2533-2549.
[20] Gremmal T,Steiner S,Seidinger D,Koppensteiner R,Panzer S,Kopp CW.The influence of proton punp inhibitors on the antiplatelet potency of clopidogrel evaluated by 5 different platelet function test.J Cardiovas Pharmocol.2010;56:532-539.